Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21952178 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL30295739 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL26822575 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL38665956 | 1.00 | USP2 (0.45) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL23172919 | 0.85 | USP2 (0.44) | USP2SMN1; SMN2GPR119RECQLHPGD | |
| SCHEMBL38665118 | 0.84 | USP2 (0.43) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL19735994 | 0.84 | USP2 (0.43) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL30626319 | 0.81 | USP2 (0.40) | USP2SMN1; SMN2GPR119RECQLHPGD | |
| SCHEMBL30626326 | 0.81 | USP2 (0.40) | USP2SMN1; SMN2GPR119RECQLHPGD | |
| SCHEMBL38666559 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2GPR119RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| CN-114206885-B | Pyrazolo [3,4-B ] pyrazines SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2025-05-02 | — | — | CN | disclosed |
| EP-4499648-A1 | PROCESS FOR PREPARING SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034160-A1 | Process For Preparing SHP2 Inhibitors | GENZYME CORPORATION (US) | 2025-01-30 | — | — | US | disclosed |
| CN-114981268-B | Pyrimidine-4 (3H) -ketone heterocyclic compound, preparation method and application thereof in medicine | 北京诺诚健华医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-112513050-B | Heterocyclic compounds which inhibit SHP2 activity | 大鹏药品工业株式会社 | 2024-12-20 | — | — | CN | disclosed |
| CN-112625028-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118871443-A | Method for preparing SHP2 inhibitor | 建新公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-10336774-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3310779-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-07-19 | — | — | US | disclosed |
| US-9938295-B2 | — | — | 2018-04-10 | — | — | US | disclosed |
| US-9938295-B2 | — | — | 2018-04-10 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336774-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885GPR119 1069/4885 |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | PTPN5, PTPRZ1, PTPN1 | USP2 2048/4885SMN1; SMN2 3093/4885GPR119 1866/4885 |
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885GPR119 1069/4885 |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | USP2 3908/4885SMN1; SMN2 3724/4885GPR119 604/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | USP2 2101/4885SMN1; SMN2 2037/4885GPR119 2016/4885 |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885GPR119 1069/4885 |
| US-20250034160-A1 | Process For Preparing SHP2 Inhibitors | PTPN7, PTPRCAP, PTPN18 | USP2 491/4885SMN1; SMN2 3016/4885GPR119 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.